Skip to main content
Edwards Lifesciences Logo
Edwards Lifesciences Logo

Promising data. Inspiring results.

inspiring results
inspiring results
inspiring results

Content relating to Edwards Lifesciences devices is intended for healthcare professionals.

Edwards Lifesciences is committed to continued scientific advancement, and studies that investigate the safety and performance of new technologies.

‌

Our trials aim to build upon one another by adding new variables which further challenge valve safety and efficacy. Our COMMENCE trial increased the patient population from the EU Feasibility trial, and the RESILIENCE trial is designed to look at different outcome measures to help further establish long-term valve durability.

Learn more about the current methodologies, promising results and conclusions of the various RESILIA tissue studies below.

RESILIA tissue is building a track record of study data.

Start YearDescription
2010Juvenile sheep study
2011EU human feasibility study in Poland
2012Aortic/mitral COMMENCE IDE study
2018RESILIENCE study begins

Pannus Formation Study

Influence of tissue technology on pannus formation on bioprosthetic heart valves1

The objective of this publication is to study the effect of RESILIA tissue on pannus formation.

Methods

  • This publication reports the outcomes of two independent studies using a juvenile sheep model of mitral valve replacement with bovine pericardial tissue
    • In an 8-month study, valves with RESILIA tissue were compared to control valves with XenoLogiX treatment (XLX)
    • In a 5-month study, valves with RESILIA tissue were compared to control valves treated with the ThermaFix process (TFX)
  • Control valves were commercially available Carpentier-Edwards PERIMOUNT mitral valves, models 6900P, and 7000TFX. Test articles were the same models configured with RESILIA tissue
  • Explanted valves were examined macroscopically and histologically. Histological observations were made by an independent pathologist, blinded to group identity
  • Independent means of pannus quantification were employed in the two studies

For a more detailed overview of the Pannus Formation Study methodology and results please download the clinical summary.

Pannus Formation Study Clinical Summary

pannus thumbnail
pannus thumbnail
pannus thumbnail
Download

Pannus Formation Study Clinical Summary

pannus thumbnail
pannus thumbnail
pannus thumbnail
Download

Juvenile Sheep Study

A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model2

The aim of the study was to assess the effects of RESILIA tissue technology on valve function and durability in a chronic sheep model. The model was designed to mirror the accelerated calcification seen in younger humans.

Methods

  • 45 juvenile sheep were randomized and either a PERIMOUNT mitral valve (6900P, control group) or the same valve design incorporating the RESILIA tissue preservation technology (test group) was implanted in the mitral position
  • All valves were 25 mm
  • A transthoracic echocardiography was performed at 1 week and at 8 months postoperatively
  • Necropsy was performed at 8 months, and the valves were examined radiographically (soft tissue radiograph), histologically (hematoxylin and eosin and Von Kossa staining), and chemically (calcium content)

For a more detailed overview of the Juvenile Sheep Study methodology and results, please see link to clinical paper details.

Juvenile Sheep Study Clinical Paper Details

Juvenile Sheep Study Clinical Paper
Juvenile Sheep Study Clinical Paper
Juvenile Sheep Study Clinical Paper
View Details

Juvenile Sheep Study Clinical Paper Details

Juvenile Sheep Study Clinical Paper
Juvenile Sheep Study Clinical Paper
Juvenile Sheep Study Clinical Paper
View Details

EU Feasibility Study

5-year outcomes after aortic valve replacement with a novel RESILIA tissue bioprosthesis3

The EU Feasibility study investigated the safety and performance in AVR patients of a bioprosthesis with RESILIA tissue. Absence of structural valve deterioration (SVD) and clinically stable transvalvular gradients were observed through 5 years.

Methods

  • Prospective, multicenter, single-arm, trial conducted at two sites
  • 133 patients underwent surgical AVR with an Edwards Pericardial Aortic Bioprosthesis with RESILIA tissue
    • Mean age 65.3 ± 13.5 years, with (26%) ≤ 60 years
    • 19 or 21 mm valve implanted in 43.6% of patients
  • Median follow up = 5 years; Total late follow-up time of 565.2 patient years (LPY)

For a more detailed overview of the EU Feasibility Study methodology and results please download the clinical summary.

EU Feasibility Study Clinical Summary

EU Feasibility Study
EU Feasibility Study
EU Feasibility Study
Download

EU Feasibility Study Clinical Summary

EU Feasibility Study
EU Feasibility Study
EU Feasibility Study
Download

COMMENCE Aortic Trial

Seven-year outcomes of the COMMENCE trial investigating aortic valve replacement with a novel tissue bioprosthesis4

The COMMENCE trial is an FDA pivotal trial designed to evaluate the safety and effectiveness of a bioprosthetic valve with the novel RESILIA tissue.

Methods

  • Prospective, multinational, multicenter (n = 27), single-arm, FDA Investigational Device Exemption trial
  • 689 patients underwent surgical AVR with the Edwards Pericardial Aortic Bioprosthesis with RESILIA tissue (model 11000A)
    • Mean age 66.9 ± 11.6 years, with 140 patients (21%) under 60 years
    • 71.8% male
    • 26% NYHA Class III/IV
    • Mean STS PROM 2.0 ± 1.8%
    • 59% isolated AVR
  • 3,435 aggregate patient-years of follow up
    • Follow up: 5.0 ± 1.9 yrs (n = 512)

For a more detailed overview of the COMMENCE trial methodology and results please download the clinical summary.

COMMENCE Trial Clinical Summary

COMMENCE Trial Thumbnnail
COMMENCE Trial Thumbnnail
COMMENCE Trial Thumbnnail
Download

COMMENCE Trial Clinical Summary

COMMENCE Trial Thumbnnail
COMMENCE Trial Thumbnnail
COMMENCE Trial Thumbnnail
Download

COMMENCE Trial Bicuspid Aortic Valve Sub-Analysis

Sub-analysis of the five-year outcomes of the COMMENCE aortic trial investigating safety outcomes and mean gradients in patients with bicuspid aortic valves.6

Methods

  • Patients underwent echocardiograms annually through 5 years of follow up; these were evaluated by a core laboratory
  • Evaluations included safety outcomes, paravalvular and transvalvular regurgitation, and summary hemodynamics
  • Longitudinal models were constructed to estimate the change in mean gradient and change in effective orifice area (EOA) separately over 5 years post-operatively

For a more detailed overview of the COMMENCE trial bicuspid aortic valve sub-analysis methodology and results, download the clinical summary.

COMMENCE Trial Bicuspid Aortic Valve Sub-Analysis Clinical Summary

bicuspid aortic thumbnail
bicuspid aortic thumbnail
bicuspid aortic thumbnail
Download

COMMENCE Trial Bicuspid Aortic Valve Sub-Analysis Clinical Summary

bicuspid aortic thumbnail
bicuspid aortic thumbnail
bicuspid aortic thumbnail
Download

RESILIENCE Study Design

Study design of the Prospective Non-Randomized Single Arm Multicenter Evaluation of the Durability of Aortic Bioprosthetic Valves with RESILIA Tissue in Subjects under 65 Years old (RESILIENCE trial)6

RESILIENCE Study Design Clinical Summary

RESILIENCE thumbnail
RESILIENCE thumbnail
RESILIENCE thumbnail
Download

The objective of the RESILIENCE trial is to determine the time to valve failure due to valve deterioration requiring re-intervention, as well as to collect/investigate early potential predictors of valve durability (e.g. calcification and hemodynamic deterioration) in RESILIA tissue. The RESILIENCE trial is the first prospective study to associate both clinical and imaging definitions of SVD with long-term (11 years) bioprosthetic valve durability.

RESILIENCE Study Design Clinical Summary

RESILIENCE thumbnail
RESILIENCE thumbnail
RESILIENCE thumbnail
Download

Methods

  • Multicenter, prospective, non-randomized, single-arm, observational trial
  • Up to 250 patients who previously underwent SAVR with a RESILIA tissue valve will be enrolled at up to 15 investigational centers across the United States and Europe
    • Includes patients <65 years old; at time of implant this is a population that is at high risk to develop SVD
    • First patient enrolled on November 21, 2018
    • Anticipated 3 year enrollment period
  • Patients undergo a TTE and non-contrast CT at 5, 7, 9, and 11 years post-valve implant (Figure 1)
  • The definition proposed by Dvir et al. includes four stages: Stage 0: no SVD; Stage 1: Morphological SVD; Stage 2: Moderate hemodynamic SVD; and Stage 3: Severe hemodynamic SVD
study flow chart
study flow chart
study flow chart
Figure 1. Study flow chart. CT: computer tomography; TTE transthoriacic echocardiography
study flow chart
study flow chart
study flow chart
Figure 1. Study flow chart. CT: computer tomography; TTE transthoriacic echocardiography

Echocardiography and CT Core Laboratories will be responsible for independently evaluating TTEs and CTs submitted by trial sites and will report upon the primary and secondary outcomes of the trial.

  • The morphology and mobility of the bioprosthetic valve leaflets will be visually assessed in multiple views by 2D echocardiography
  • Non-contrast CT images will be acquired using a 64 slice or dual-source scanner
    • Valve leaflet calcification will be measured by the volumetric method that identifies calcium within the valve leaflets
    • The total volume of calcification over the 3 valve leaflets will be calculated and expressed in mm3

The RESILIENCE trial will be the first prospective study that uses both clinical and imaging definitions of SVD to provide a comprehensive description of all stages of SVD and determine the long-term (11 years) durability of the RESILIA tissue in a aortic valve.

For a more detailed overview of the RESILIENCE study methodology, please download the clinical summary.

Featured Products

Explore our current RESILIA tissue products

inspiris resilia
inspiris resilia
inspiris resilia

INSPIRIS RESILIA aortic valve

mitris resilia thumb
mitris resilia thumb
mitris resilia thumb

MITRIS RESILIA mitral valve

Inquiries

If you would like further information about our privacy policy, please click here.

Would you like to opt-in to receive future email communications from Edwards Lifesciences?

This includes notification of future symposia, forums, conference activities, product updates, and educational events.

References

  1. Tod reference is: TJ Tod et al. Cardiovasc Eng Technol 2021;12:418-25.
  2. Flameng W, et al. J Thorac Cardiovasc Surg. 2015;149:340–5.
  3. Bartus K et al. Eur J Cardiothorac Surg 2021;59:434-41.
  4. Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2023 Sep 29:S0022-5223(23)00873-5.Epub ahead of print. PMID: 37778503.
  5. Mumtaz MA, Bavaria JE, Griffith B, et al. Presented at the Society of Thoracic Surgeons Annual Meetings, January 2022.
  6. Pibarot P, et al. Structural Heart. 2020;4(1):46-52.